We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?
Read MoreHide Full Article
Masimo Corporation’s (MASI - Free Report) third-quarter 2018 earnings are scheduled to release on Oct 31, after market close.
Product revenues are likely to drive quarterly results and a raised guidance for 2018 is another encouraging factor.
Q2 Results at a Glance
In the last reported quarter, Masimo posted adjusted earnings of 73 cents per share, which beat the Zacks Consensus Estimate by a penny. Earnings surged 32.7% on a year-over-year basis.
Revenues improved 10% year over year to $211.6 million and surpassed the Zacks Consensus Estimate of $208 million.
The company has a positive average earnings surprise of 14.7% for the trailing four quarters.
Masimo reports through two major segments — Product sales and Royalty & Other revenues.
Which Way Are Estimates Treading?
For the quarter to be reported, the Zacks Consensus Estimate for Masimo’s earnings is pegged at 68 cents, showing a year-over-year decline of 2.9%. The same for revenues stands at $206.3 million, reflecting an increase of 6.5% year over year.
Masimo’s Product revenues have been consistently driving its top line. The business includes Masimo’s flagship Signal Extraction Technology (SET) Pulse Oximetry which has been much in demand of later. The company’s rainbow Pulse CO-Oximetry measures blood constituents and SET measurements of oxygen saturation.
In the last reported quarter, the segment contributed 95.5% to net sales. Sales in the segment grossed $202 million, up 12.4% from the year-ago quarter and 11.2% at constant currency (cc).
It is encouraging to note that for the third quarter, the Zacks Consensus Estimate for the segment’s revenues is pegged at $198 million, up 9.4% on a year-over-year basis. In fact, for 2018, the company expects Product revenues to be $822 million, up from the previously projected $818 million.
Other Factors at Play
Raised Guidance
For 2018, Masimo expects revenues of $850 million, up from the previous guidance of $846 million. Notably, this reflects growth of 10.8% at cc. The Zacks Consensus Estimate stands at $850.2 million, slightly above the projected figure.
Adjusted earnings per share are expected at $2.90, up from the earlier estimated figure of $2.88. The Zacks Consensus Estimate for the same is pegged at $2.90, in line with the guided figure.
Streak of Recent Positive Study Results
In August 2018, Masimo announced the findings of a study which proved the ability of Masimo ORi (Oxygen Reserve Index) to show trends in oxygenation in the moderate hyperoxic region (partial pressure of oxygen in arterial blood [PaO2] in the range of 100 to 200 mmHg).
Furthermore, Masimo announced that its SET Measure-through Motion and Low Perfusion pulse oximetry might be a useful initial screening method to identify children with Down Syndrome (DS) who are at a high risk of obstructive sleep apnea (OSA).
We expect these developments to favor the company this earnings season.
What Does Our Model Say?
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the quarter. This is precisely the case here.
Earnings ESP: Masimo has an Earnings ESP of +0.98%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Masimo carries a Zacks Rank #2.
Please note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter.
PerkinElmer has an Earnings ESP of +1.45% and a Zacks Rank #3.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.43% and a Zacks Rank #3.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Will Product Revenues Drive Masimo's (MASI) Q3 Earnings?
Masimo Corporation’s (MASI - Free Report) third-quarter 2018 earnings are scheduled to release on Oct 31, after market close.
Product revenues are likely to drive quarterly results and a raised guidance for 2018 is another encouraging factor.
Q2 Results at a Glance
In the last reported quarter, Masimo posted adjusted earnings of 73 cents per share, which beat the Zacks Consensus Estimate by a penny. Earnings surged 32.7% on a year-over-year basis.
Revenues improved 10% year over year to $211.6 million and surpassed the Zacks Consensus Estimate of $208 million.
The company has a positive average earnings surprise of 14.7% for the trailing four quarters.
Masimo reports through two major segments — Product sales and Royalty & Other revenues.
Which Way Are Estimates Treading?
For the quarter to be reported, the Zacks Consensus Estimate for Masimo’s earnings is pegged at 68 cents, showing a year-over-year decline of 2.9%. The same for revenues stands at $206.3 million, reflecting an increase of 6.5% year over year.
Masimo Corporation Price and EPS Surprise
Masimo Corporation Price and EPS Surprise | Masimo Corporation Quote
Product Revenues Likely to Drive Q3
Masimo’s Product revenues have been consistently driving its top line. The business includes Masimo’s flagship Signal Extraction Technology (SET) Pulse Oximetry which has been much in demand of later. The company’s rainbow Pulse CO-Oximetry measures blood constituents and SET measurements of oxygen saturation.
In the last reported quarter, the segment contributed 95.5% to net sales. Sales in the segment grossed $202 million, up 12.4% from the year-ago quarter and 11.2% at constant currency (cc).
It is encouraging to note that for the third quarter, the Zacks Consensus Estimate for the segment’s revenues is pegged at $198 million, up 9.4% on a year-over-year basis. In fact, for 2018, the company expects Product revenues to be $822 million, up from the previously projected $818 million.
Other Factors at Play
Raised Guidance
For 2018, Masimo expects revenues of $850 million, up from the previous guidance of $846 million. Notably, this reflects growth of 10.8% at cc. The Zacks Consensus Estimate stands at $850.2 million, slightly above the projected figure.
Adjusted earnings per share are expected at $2.90, up from the earlier estimated figure of $2.88. The Zacks Consensus Estimate for the same is pegged at $2.90, in line with the guided figure.
Streak of Recent Positive Study Results
In August 2018, Masimo announced the findings of a study which proved the ability of Masimo ORi (Oxygen Reserve Index) to show trends in oxygenation in the moderate hyperoxic region (partial pressure of oxygen in arterial blood [PaO2] in the range of 100 to 200 mmHg).
Furthermore, Masimo announced that its SET Measure-through Motion and Low Perfusion pulse oximetry might be a useful initial screening method to identify children with Down Syndrome (DS) who are at a high risk of obstructive sleep apnea (OSA).
We expect these developments to favor the company this earnings season.
What Does Our Model Say?
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise in the quarter. This is precisely the case here.
Earnings ESP: Masimo has an Earnings ESP of +0.98%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Masimo carries a Zacks Rank #2.
Please note that we caution against stocks with a Zacks Rank #4 (Sell) or 5 (Strong Sell) going into the earnings announcement, especially when the company is seeing negative estimate revision.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering as they also have the right combination of elements to post an earnings beat this quarter.
PerkinElmer has an Earnings ESP of +1.45% and a Zacks Rank #3.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.43% and a Zacks Rank #3.
Baxter International (BAX - Free Report) has an Earnings ESP of +0.90% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>